Jose A Martinez-Climent

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. pmc Lymphoma stem cells: enough evidence to support their existence?
    Jose A Martinez-Climent
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Avda Pio XII, 55 31008 Pamplona, Spain
    Haematologica 95:293-302. 2010
  2. ncbi request reprint Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer
    Joan Climent
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, and Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Cancer Res 67:818-26. 2007
  3. ncbi request reprint Somatic stem cells and the origin of cancer
    Jose A Martinez-Climent
    Division of Oncology, Center for Applied Medical Research University of Navarra, Pamplona, Spain
    Clin Transl Oncol 8:647-63. 2006
  4. ncbi request reprint Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
    Cinta Mestre-Escorihuela
    Center for Applied Medical Research CIMA, University of Navarra, Avda Pio XII, 55, Pamplona 31008, Spain
    Blood 109:271-80. 2007
  5. ncbi request reprint Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations
    Jose A Martinez-Climent
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Blood 101:3109-17. 2003
  6. doi request reprint Integrative oncogenomic analysis of microarray data in hematologic malignancies
    Jose A Martinez-Climent
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Methods Mol Biol 576:231-77. 2010
  7. ncbi request reprint Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma
    Jose A Martinez-Climent
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Avda Blasco Ibanez, 17 46010 Valencia, Spain
    Leuk Lymphoma 44:459-64. 2003
  8. doi request reprint Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
    Jose A Richter-Larrea
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Blood 116:2531-42. 2010
  9. ncbi request reprint Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
    Fanny Rubio-Moscardo
    Center for Applied Medical Research CIMA, Division of Oncology, University of Navarra, Avda Pio XII, 55, Pamplona 31008, Spain
    Blood 106:3214-22. 2005
  10. ncbi request reprint Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome
    Fanny Rubio-Moscardo
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Blood 105:4445-54. 2005

Collaborators

Detail Information

Publications19

  1. pmc Lymphoma stem cells: enough evidence to support their existence?
    Jose A Martinez-Climent
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Avda Pio XII, 55 31008 Pamplona, Spain
    Haematologica 95:293-302. 2010
    ....
  2. ncbi request reprint Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer
    Joan Climent
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, and Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Cancer Res 67:818-26. 2007
    ..However, these initial findings should be evaluated in randomized clinical trials...
  3. ncbi request reprint Somatic stem cells and the origin of cancer
    Jose A Martinez-Climent
    Division of Oncology, Center for Applied Medical Research University of Navarra, Pamplona, Spain
    Clin Transl Oncol 8:647-63. 2006
    ....
  4. ncbi request reprint Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
    Cinta Mestre-Escorihuela
    Center for Applied Medical Research CIMA, University of Navarra, Avda Pio XII, 55, Pamplona 31008, Spain
    Blood 109:271-80. 2007
    ..Our microarray strategy has identified novel candidate tumor suppressor genes inactivated by genetic and epigenetic mechanisms that substantially vary among the B-NHL subtypes...
  5. ncbi request reprint Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations
    Jose A Martinez-Climent
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Blood 101:3109-17. 2003
    ..This process is associated with the acquisition of a variable spectrum of genomic imbalances affecting recurrent chromosomal areas that harbor overexpressed or underexpressed genes targeted upon transformation...
  6. doi request reprint Integrative oncogenomic analysis of microarray data in hematologic malignancies
    Jose A Martinez-Climent
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Methods Mol Biol 576:231-77. 2010
    ..We also present the basic aspects of these methodologies and their present and future application in clinical oncology...
  7. ncbi request reprint Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma
    Jose A Martinez-Climent
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Avda Blasco Ibanez, 17 46010 Valencia, Spain
    Leuk Lymphoma 44:459-64. 2003
    ..We hypothesize that the trisomy of 3q may correlate with the indolent nature of SMZL, and that the loss of this acquired abnormality leads to or accompanies the development of blastic tumors...
  8. doi request reprint Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
    Jose A Richter-Larrea
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Blood 116:2531-42. 2010
    ..We suggest that the combination of histone-deacetylase inhibitors and high-dose chemotherapy may overcome chemoresistance, achieve durable remission, and improve survival of patients with BL...
  9. ncbi request reprint Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
    Fanny Rubio-Moscardo
    Center for Applied Medical Research CIMA, Division of Oncology, University of Navarra, Avda Pio XII, 55, Pamplona 31008, Spain
    Blood 106:3214-22. 2005
    ..Our data suggest that TRAIL-R1 and TRAIL-R2 act as dosage-dependent tumor suppressor genes whose monoallelic deletion can impair TRAIL-induced apoptosis in B-cell lymphoma...
  10. ncbi request reprint Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome
    Fanny Rubio-Moscardo
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Spain
    Blood 105:4445-54. 2005
    ..3 to 15.7). Our study highlights the genomic profile as a predictor for clinical outcome and suggests that "genome scanning" of chromosomes 1p21, 9q21-q22, 9p21.3-P16/INK4a, and 17p13.1-TP53 may be clinically useful in MCL...
  11. doi request reprint Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia
    Edurne San Jose-Eneriz
    Hematology Department and Area of Cell Therapy, Clinica Universitaria, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain
    Eur J Cancer 45:1877-89. 2009
    ..However, the mechanisms involved in the regulation of BIM in CML and its role in the clinical setting have not been established...
  12. ncbi request reprint Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer
    Joan Climent
    Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Valencia, Spain 46010
    Clin Cancer Res 8:3863-9. 2002
    ..Furthermore, the genomic loss of 18p may identify a poor prognostic subgroup of patients with HRBC...
  13. pmc Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells
    Beatriz Aldaz
    Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e77098. 2013
    ..Our study uncovers the microRNA dynamic expression changes occurring during differentiation of GICs, and identifies miR-21 and miR-221/222 as key regulators of this process. ..
  14. pmc A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma
    Elena Beltran
    Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Proc Natl Acad Sci U S A 108:12461-6. 2011
    ..This effective combination therapy also might be exploited in other cyclin-D1-expressing tumors...
  15. doi request reprint LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas
    Cristina Bertolo
    Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Br J Haematol 162:621-30. 2013
    ....
  16. pmc Downregulation of FOXP1 is required during germinal center B-cell function
    Ainara Sagardoy
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Blood 121:4311-20. 2013
    ..These studies show that FOXP1 is physiologically downregulated in GC B cells and that aberrant expression of FOXP1 impairs mechanisms triggered by B-cell activation, potentially contributing to B-cell lymphomagenesis...
  17. ncbi request reprint Genomic profiling of mantle cell lymphoma
    Melissa Rieger Menanteau
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Methods Mol Biol 973:147-63. 2013
    ....
  18. pmc LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome
    Raquel Malumbres
    Division of Oncology, Center for Applied Medical Research CIMA University of Navarra, Pamplona, Spain
    Haematologica 96:980-6. 2011
    ..The implication of LMO2 in B-cell acute lymphoblastic leukemia must still be explored...
  19. ncbi request reprint Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
    Vicente Fresquet
    Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain and
    Blood 123:4111-9. 2014
    ..These results anticipate the potential development of such mutations in patients treated with ABT-199, providing a basis to preventing their occurrence and to designing drugs able to circumvent the acquired resistance. ..